Olink

Name

Olink

Legal name

Olink Proteomics AB

Website

https://olink.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Proteomics Research Tools

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Proteomics & Biomarker Analytical Testing (HLAGADAG)

akta.pro secondary industries

Proteomics & Mass Spectrometry Services (HLAGANAB), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Translational Medicine & Biomarkers (HLAIALAF), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Proteomics assays
• Protein biomarker analysis
• Multiplex immunoassay kits
• Biomarker discovery services
• Life sciences research tools

Headquarters

HQ city

Uppsala

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. Proteomics Instruments: Sale of Olink Signature Q100 instruments and related hardware to research institutions and pharmaceutical companies for in-house proteomics capabilities.
2. Assay Kits and Reagents: Recurring revenue from sale of PEA-based assay kits including Explore, Target, Flex, and Focus product lines. Kits contain antibody pairs, detection reagents, and consumables for specific protein biomarker panels.
3. Analysis Services: Olink operates certified service provider network and offers direct analysis services for customers who prefer outsourced proteomics testing rather than running assays in-house.
4. Data Science Services: Consulting and bioinformatics services to help customers design studies, analyze proteomics data, and generate insights from biomarker discoveries.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Olink develops and sells proprietary proteomics instruments, multiplex assay kits, and bioinformatics software built on its patented Proximity Extension Assay (PEA) technology for high-throughput protein biomarker analysis. Its product lines include the Olink Explore HT discovery platform, Olink Reveal NGS-based platform, Olink Target 96/48 targeted panels, Olink Flex and Focus custom kits, and the Olink Signature Q100 automated instrument, complemented by Olink Insight/Analyze/NPX software and outsourced Analysis and Data Science Services. Customers are pharmaceutical and biotechnology companies, academic research institutions, and clinical research organizations using these tools for biomarker discovery, drug target identification, patient stratification, and clinical trial research.

Product overview

Olink is a next-generation proteomics company (now part of Thermo Fisher Scientific) offering a platform-plus-products architecture based on its proprietary Proximity Extension Assay (PEA) technology. The portfolio centers on Olink Explore HT as the flagship high-throughput discovery platform, complemented by the modular Olink Explore 3072/384 (being discontinued in 2026) and Olink Reveal for NGS-based proteomics. The Olink Target series provides hypothesis-driven targeted proteomics with Olink Target 96 (11 panels, 88 proteins each), Olink Target 48 (Cytokine and Immune Surveillance panels), Olink Target 48 Neurodegeneration, and Olink Target 48 Mouse. Supporting offerings include Olink Flex and Olink Focus for flexible/focused applications, Olink Concordance Test for quality control, and the Olink Signature Q100 instrument. Software includes Olink Insight (bioinformatics), Olink Analyze, and NPX Software for data analysis. Services encompass Olink Analysis Services and Olink Data Science Services. Olink also fosters research collaboration through consortia including SCALLOP (proteogenomics), CORAL (neurology), and COLLIBRI (IBD). The company reports over 4,000 peer-reviewed publications demonstrating platform utility across cardiovascular, immunology, oncology, neurology, and metabolic disease research.

Differentiator

Problem solved

Functional benefit

Brands

• Olink Explore: High-throughput proteomics platform for hypothesis-driven biomarker discovery
• Olink Target
• Olink Reveal
• Olink Flex
• Olink Focus
• Olink Signature Q100
• Olink Insight
• Olink Analyze
• NPX Software
• Olink Shield

Products and services

• Olink Explore HT Next-generation high-throughput proteomics platform for discovery-scale protein biomarker analysis, measuring over 5,400 protein biomarkers from small blood samples (1 µL) using PEA technology with NGS readout, for population-scale proteogenomics studies by pharma, biotech, and academic customers.
• Olink Reveal

Quantifiable outcome

• Over 5,400 protein biomarkers measurable from small sample volumes
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core and strategic.

• CORAL ConsortiumcoreStrategic or Co-development Partner · 1 July 2021CORAL (Community using Olink for Research on Alzheimer's Disease and other neurological diseases) is a collaborative framework dedicated to accelerating identification of proteins and mechanisms for neurological diseases and translation of novel biomarkers to clinic. Includes research on Alzheimer's, Parkinson's, FTD, MS, ALS, and other neurological conditions.
• UK BiobankcoreStrategic or Co-development PartnerLandmark partnership for population-scale proteogenomics research. UK Biobank is utilizing Olink's PEA technology for their ambitious proteomics program analyzing hundreds of thousands of participants, resulting in multiple high-impact Nature publications demonstrating the power of discovery-scale proteomics integrated with genomic data.
• SCALLOP ConsortiumcoreStrategic or Co-development PartnerSCALLOP (Systematic and Combined AnaLysis of Olink Proteins) is a collaborative consortium comprising numerous PIs from various research institutions contributing summary-level data from over 70,000 patients and controls across 45+ cohort studies. Focuses on discovering and following up on genetic associations with proteins on Olink's PEA platform.
• COLLIBRI ConsortiumcoreStrategic or Co-development PartnerCOLLIBRI is a consortium aimed at accelerating progress in inflammatory bowel disease research through protein biomarkers. Engages both academic and industrial partners to share clinical samples and data, generating novel insights into disease pathogenesis and biomarker signatures at proteomic level.
• Strand Life Sciences (Reliance Industries)strategicTechnology or IntegrationStrand Life Sciences, a Reliance Industries subsidiary, has launched advanced proteomics capabilities enabled by the Olink Explore HT platform, enabling measurement of over 5,400 protein biomarkers from small blood samples for integrated multi-omics research and drug discovery in India and South Asia.
• Thermo Fisher ScientificcoreOthersThermo Fisher Scientific completed acquisition of Olink in July 2024 for approximately $3.1 billion. Olink operates as a business unit within Thermo Fisher, combining its proteomics capabilities with Thermo Fisher's existing life sciences tools portfolio including mass spectrometry, CRO/CDMO services, and AI-enabled data platforms.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Meso Scale Diagnostics: Provides multiplex immunoassay platforms (Meso Scale Discovery / MSD) for protein biomarker analysis. Competes with Olink Target panels in pharma and clinical research for sensitive, high-throughput protein measurement.
• Quanterix: Single-molecule array (Simoa) technology for ultra-sensitive protein detection. Competes with Olink in neurology and biomarker discovery, particularly where detection of low-abundance proteins is required.
• SomaLogic (now Standard BioTools): Direct competitor in high-plex protein biomarker discovery using its SomaScan platform (aptamer-based). Now part of Standard BioTools, the merged entity competes directly with Olink's PEA technology across pharma and academic accounts.

Broad incumbents

• 10x Genomics: Single-cell and spatial genomics platforms with growing proteomics and multi-omics capabilities. Overlaps with Olink in translational research and population-scale biology applications.
• Bio-Rad Laboratories: Diversified life sciences tools company with protein analysis offerings including Bio-Plex multiplex assays. Competes broadly with Olink in proteomics workflows and serves overlapping pharma and academic customers.
• Thermo Fisher Scientific: Olink's parent company and the largest life sciences tools provider, offering Orbitrap mass spectrometry for proteomics and PPD CRO services. Internal overlap creates both synergy and channel conflict considerations.
• Bruker: Mass spectrometry and proteomics instrumentation provider (timsTOF, timsMetabo). Competes with Olink's protein biomarker workflows in discovery proteomics and pharma applications.

Emerging players

• Cytek Biosciences: Flow cytometry and cell analysis company expanding into high-parameter immune profiling. Adjacent to Olink's immunology and immuno-oncology panels, particularly in translational and clinical research settings.
• Seer: Proteomics platform leveraging nanoparticle-based enrichment for deep, unbiased proteome analysis. Competes with Olink Explore in discovery-scale proteomics applications.
• Nautilus Biotechnology: Emerging proteomics platform using single-molecule analysis to characterize the full proteome. Represents a potential long-term disruptor to Olink's targeted/affinity-based multiplexing approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@olinkproteomics
• LinkedInlinkedin.com/company/olink-proteomics
• Xx.com/olinkproteomics

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Olink